SHR 1906
Alternative Names: SHR-1906Latest Information Update: 08 May 2023
At a glance
- Originator Guangdong Hengrui Pharmaceutical
- Class Antifibrotics; Antineoplastics
- Mechanism of Action Connective tissue growth factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Idiopathic pulmonary fibrosis
Most Recent Events
- 28 Mar 2023 Phase-II clinical trials in Idiopathic pulmonary fibrosis (Treatment-experienced) in China (IV) (NCT05722964)
- 10 Feb 2023 Guangdong Hengrui Pharmaceutical plans a phase II trial for Idiopathic pulmonary fibrosis (Treatment-experienced) in February 2023 (IV, Injection) (NCT05722964)
- 07 Sep 2022 Guangdong Hengrui Pharmaceutical completes the phase I trial in Pulmonary fibrosis in China (NCT04986540)